Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

The initiative, titled 'The Court Is Hers,' eliminates registration fees for girls basketball programs at the YMCA.

The up to $100 million in state tax incentives for a $3 billion Eli Lilly expansion in Kenosha County isn’t the only tax incentive for the project. The expansion is also part of a tax increment ...